Pegunigalsidase alfa-iwxj
Products billed under this code include Elfabrio.
Payment limit per 1 MG, by effective quarter, 4Q24 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Elfabrio.
Payment limit per 1 MG, by effective quarter, 4Q24 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Elfabrio | Chiesi USA, Inc. | 10122-0160-02 | 20 | $4,519.96 |
| Elfabrio | Chiesi USA, Inc. | 10122-0160-05 | 100 | $22,599.80 |
| Elfabrio | Chiesi USA, Inc. | 10122-0160-10 | 200 | $45,199.60 |
| Elfabrio | Chiesi USA, Inc. | 10122-0165-02 | 5 | $1,129.99 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $225.998 | +$0.333 | 1 MG | Pegunigalsidase alfa-iwxj | v1, posted September 17, 2026 |
| 3Q26 | $225.665 | +$2.265 | 1 MG | Pegunigalsidase alfa-iwxj | v1, posted September 15, 2026 |
| 2Q26 | $223.40 | −$2.548 | 1 MG | Pegunigalsidase alfa-iwxj | v1, posted September 15, 2026 |
| 1Q26 | $225.948 | −$2.207 | 1 MG | Pegunigalsidase alfa-iwxj | v1, posted September 15, 2026 |
| 4Q25 | $228.155 | −$2.123 | 1 MG | Pegunigalsidase alfa-iwxj | v1, posted September 8, 2026 |
| 3Q25 | $230.278 | +$3.351 | 1 MG | Pegunigalsidase alfa-iwxj | v1, posted March 10, 2026 |
| 2Q25 | $226.927 | +$0.134 | 1 MG | Pegunigalsidase alfa-iwxj | v1, posted March 10, 2026 |
| 1Q25 | $226.793 | +$3.246 | 1 MG | Pegunigalsidase alfa-iwxj | v1, posted December 19, 2025 |
| 4Q24 | $223.547 | – | 1 MG | Pegunigalsidase alfa-iwxj | v1, posted June 11, 2025 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.